Home / Business and Economy / AbbVie Invests $380M in US Pharma Production
AbbVie Invests $380M in US Pharma Production
24 Feb
Summary
- AbbVie will invest $380 million in two new facilities.
- New plants will increase domestic capacity for neuroscience and obesity medicines.
- Construction begins spring 2026, operational by 2029, creating 300 jobs.
AbbVie announced a substantial $380 million investment to establish two new manufacturing facilities on its Illinois campus. These facilities will enhance the company's domestic production capabilities, specifically for neuroscience and obesity medicines, addressing a growing need for U.S.-based pharmaceutical manufacturing.
The construction phase is scheduled to commence in the spring of 2026. Both new sites are anticipated to be fully operational by 2029. This expansion is part of a wider strategy to bolster U.S. manufacturing capacity and domestic inventory, aligning with industry trends.
These advanced facilities will incorporate cutting-edge manufacturing technologies and artificial intelligence to support the production of future medicines. The project is also expected to generate 300 new employment opportunities in North Chicago, including roles for engineers, scientists, and manufacturing operators.
